Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission

NCT01618305 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

408

Enrollment

OTHER

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Lamivudine/zidovudine
DRUG: Efavirenz
DRUG: Raltegravir

Sponsor

Westat

Collaborators

[object Object]
[object Object]